Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

USFDA rejects SPARC's cancer drug application

SPARC is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.

February 11, 2020 / 09:09 PM IST
Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharma Advanced Research Company (SPARC) on Tuesday said the US health regulator has not approved its new drug application for Taclantis, its under development product for treatment of breast cancer. "The company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension)," SPARC said in a regulatory filing.

SPARC is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.

As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.

On July 1 last year, the company had announced that the USFDA had accepted for review SPARC's NDA for Taclantis.

The company's NDA filing was based on successful demonstration of clinical bioequivalence of Taclantis with Abraxane and associated clinical safety data.

Abraxane is indicated for treatment of breast cancer, lung cancer among others.

In 2017, USFDA had denied approval to SPARC's new drug application for Elepsia XR, an anti-epileptic drug.

Shares of SPARC on Tuesday ended 3.63 per cent lower at Rs 191.15 apiece on the BSE.

PTI
first published: Feb 11, 2020 09:04 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347